Literature DB >> 31186893

Controversies in hepatitis C therapy: Reactivation of hepatitis B virus.

Sarah R Lieber1, Michael W Fried1.   

Abstract

Entities:  

Year:  2017        PMID： 31186893      PMCID： PMC6499226          DOI： 10.1002/cld.665

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  28 in total

1.  Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients.

Authors:  Giovanni Raimondo; Maurizia R Brunetto; Patrizia Pontisso; Antonina Smedile; Anna Maria Maina; Carlo Saitta; Giovanni Squadrito; Natascia Tono
Journal:  Hepatology       Date:  2006-01       Impact factor: 17.425

2.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

3.  Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.

Authors:  Cindy M Weinbaum; Ian Williams; Eric E Mast; Susan A Wang; Lyn Finelli; Annemarie Wasley; Stephanie M Neitzel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2008-09-19

4.  Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions.

Authors:  Edmund J Bini; Ponni V Perumalswami
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

5.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Authors:  George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

6.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

Authors:  Winnie Yeo; Tung C Chan; Nancy W Y Leung; Wai Y Lam; Frankie K F Mo; Miu Ting Chu; Henry L Y Chan; Edwin P Hui; Kenny I K Lei; Tony S K Mok; Paul K S Chan
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene.

Authors:  Virginie Williams; Ségolène Brichler; Nadjia Radjef; Pierre Lebon; Anne Goffard; Didier Hober; Remi Fagard; Dina Kremsdorf; Paul Dény; Emmanuel Gordien
Journal:  J Gen Virol       Date:  2009-07-22       Impact factor: 3.891

8.  Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.

Authors:  Ann-Lii Cheng; Chao A Hsiung; Ih-Jen Su; Pei-Jer Chen; Ming-Chih Chang; Chao-Jung Tsao; Woei-Yao Kao; Wu-Ching Uen; Chih-Hung Hsu; Hwei-Fan Tien; Tsu-Yi Chao; Li-Tzong Chen; Jacqueline Whang-Peng
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

9.  Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein.

Authors:  Christian G Schüttler; Nicola Fiedler; Katja Schmidt; Reinald Repp; Wolfram H Gerlich; Stephan Schaefer
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

10.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.